We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Capillary Film Technology Receives £98K Funding
News

Capillary Film Technology Receives £98K Funding

Capillary Film Technology Receives £98K Funding
News

Capillary Film Technology Receives £98K Funding

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Capillary Film Technology Receives £98K Funding "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Capillary Film Technology Limited (CFT) announced it has received £98K in funding as part of a Small Business Research Initiative for Healthcare (SBRI Healthcare) development contract. The funding will be used to develop a cost-effective and fully quantitative multiplexed point-of-care (POC) testing technology to aid in the assessment of acute coronary syndrome.

The POC diagnostic is based on CFT’s FluorEx™ technology, a low-cost microfluidic fluoropolymer film that possesses unique optical transparency. FluorEx uses a parallel array of 10 x 200 micron capillaries to enable rapid fully quantitative immunoassays to be incorporated in existing or emergent diagnostic technologies. The technology has the potential to provide a cost effective quantitative option for diagnosing acute coronary syndrome, resulting in reduced waiting times and improved treatment for patients. CFT’s FluorEx technology is available for licensing.

Commenting on the funding, Dr Lee Smith, CEO at CFT, said: “Our vision is to develop a next-generation lateral flow diagnostic testing technology that can measure multiple clinically relevant biomarkers, such as those used to select treatments for patients presenting with symptoms of acute cardiac syndrome, but with the low cost and simplicity required by emergency medics, paramedics, and GPs. This funding will enable us to focus on developing a diagnostic technology that meets the specific needs of NHS patients, and ultimately improve the health of patients suffering from heart attacks.”

Advertisement